Abstract: A compound having a structure as shown in general formula (I), a deuterated compound, a stereoisomer, or a pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising same, and use thereof. The compound has a good PIM kinase inhibitory effect, is a novel and ideal PIM inhibitor having high activity and low toxicity, and can be used for treating and/or preventing hematoma such as acute myeloid leukemia, bone marrow fibrosis and chronic lymphocytic leukemia, solid tumors such as gastric cancer and prostate cancer, and other diseases.

Abstract: Disclosed is a pyrazolopyrimidine derivative having a structure represented by general formula (I), a pharmaceutically acceptable salt, hydrate and metabolite formed by metabolism in any form thereof, and use in preparing drugs for preventing and/or treating indications associated with JAK kinase function, and a pharmaceutical composition prepared therefrom for preventing and/or treating indications associated with JAK kinase function. The present disclosure is a selective JAK kinase inhibitor, which has a pharmaceutical therapeutic effect on immunity and inflammatory responses by acting on JAK kinase.

Abstract: The present invention relates to a pyrrolopyrimidine five-membered azacyclic derivative as a novel JAK kinase inhibitor, and use thereof in a preparation of a pharmaceutical product for preventing and/or treating an indication related to a JAK kinase function. The pyrrolopyrimidine five-membered azacyclic derivative of the invention is an ideal JAK kinase inhibitor with a high potency, and can be used to treat or prevent diseases such as rheumatoid arthritis, polycythemia vera, psoriasis, primary thrombocytosis, myelofibrosis, and the like.

Abstract: Provided are a novel quinoline derivative, or a pharmaceutically acceptable salt, a hydrate, or a metabolite formed by metabolism in any form thereof, and use thereof in preparing a medicine for preventing and/or treating indications associated with angiogenesis. The quinoline derivative is an ideal and high-efficiency VEGFR inhibitor, and is able to be used to treat or prevent tumour growth and other metastasis growth diseases associated with angiogenesis.

Abstract: Imidazopyrazinamine phenyl derivatives, pharmaceutically acceptable salts and hydrates thereof, or metabolites thereof formed by any form of metabolism, and uses thereof in the preparation of medicaments for preventing and/or treating indications/diseases associated with BTK functions are disclosed. The disclosed imidazopyrazinamine phenyl derivatives are ideal high-efficient BTK inhibitors for treating or preventing diseases such as rheumatoid arthritis, B cell lymphoma, leukemia, multiple myeloma, allergies, asthma, multiple sclerosis, type I diabetes and systemic lupus erythematosus.

Abstract: Disclosed are crystal forms K, E, F and G of the dimaleate of the compound as shown in formula I, and preparation methods and uses thereof. The crystal forms K, E, F and G have superior storage stability and solubility, so that they are more suitable for being used as the drug substance for drug product preparations.

Abstract: Imidazopyrazinamine phenyl derivatives, pharmaceutically acceptable salts and hydrates thereof, or metabolites thereof formed by any form of metabolism, and uses thereof in the preparation of medicaments for preventing and/or treating indications/diseases associated with BTK functions are disclosed. The disclosed imidazopyrazinamine phenyl derivatives are ideal high-efficient BTK inhibitors for treating or preventing diseases such as rheumatoid arthritis, B cell lymphoma, leukemia, multiple myeloma, allergies, asthma, multiple sclerosis, type I diabetes and systemic lupus erythematosus.

Abstract: Provided are a novel quinoline derivative, or a pharmaceutically acceptable salt, a hydrate, or a metabolite formed by metabolism in any form thereof, and use thereof in preparing a medicine for preventing and/or treating indications associated with angiogenesis. The quinoline derivative is an ideal and high-efficiency VEGFR inhibitor, and is able to be used to treat or prevent tumour growth and other metastasis growth diseases associated with angiogenesis.

Abstract: A pyrrolopyrimidine five-membered azacyclic derivative as a novel JAK kinase (Janus kinase) inhibitor, and use thereof in a preparation of a pharmaceutical product for preventing and/or treating an indication related to a JAK kinase function. The pyrrolopyrimidine five-membered azacyclic derivative is an ideal JAK kinase inhibitor with a high potency, and can be used to treat or prevent diseases such as rheumatoid arthritis, polycythemia vera, psoriasis, primary thrombocytosis, myelofibrosis, and the like.

Abstract: Disclosed are crystal forms K, E, F and G of the dimaleate of the compound as shown in formula I, and preparation methods and uses thereof. The crystal forms K, E, F and G have superior storage stability and solubility, so that they are more suitable for being used as the drug substance for drug product preparations.

Abstract: Disclosed are crystal forms K, E, F and G of the dimaleate of the compound as shown in formula I, and preparation methods and uses thereof. The crystal forms K, E, F and G have superior storage stability and solubility, so that they are more suitable for being used as the drug substance for drug product preparations.

Abstract: Disclosed are crystal forms K, E, F and G of the dimaleate of the compound as shown in formula I, and preparation methods and uses thereof. The crystal forms K, E, F and G have superior storage stability and solubility, so that they are more suitable for being used as the drug substance for drug product preparations.

Abstract: The invention discloses a new amino-quinazoline derivative and its use in preparing drugs for preventing and/or treating malignancies. The amino-quinazoline derivative of the invention is an ideal, high effective, dual and irreversible EGFR and HER2 kinase inhibitor, and can treat or prevent various malignancy diseases, such as breast cancer, ovarian cancer, gastrointestinal cancer, oesophageal cancer, lung cancer, head and neck squamous cancer, pancreatic cancer, epidermis squamous cell cancer, prostatic cancer, neuroglioma and nasopharynx cancer.

Abstract: The measurement of multiple membrane affinities of test compounds, methods and compositions useful for acquiring data characteristic of such affinities, and a method and system for using such data alone or in combination with other molecular descriptors for the prediction of biological activity are described. The numerical values characteristic of biologically relevant interaction of test compounds with membrane mimetic surfaces are compared with corresponding values of one or more control compounds having a known biological activity. Probable biological activity of a test compound is identified with those control compounds whose multiple membrane interaction values most closely correlate to those of the test compound.

Abstract: This invention relates to a high efficiency chromatographic system. More specifically, the present invention relates to a chromatographic system for determining the physicochemical properties of one or more compounds using at least two chromatographic units in eluent flow communication with one eluent analyzer via an intermediate eluent switch. The present chromatographic system allows determination of physicochemical properties through the use of multiple chromatographic units in communication with one eluent analyzer via an eluent switch.

Abstract: Methods are provided for determining a dissociation constant for each one of at least a portion of a set of compounds. The methods include contacting a solution of the set of compounds with a membrane mimetic surface exhibiting a non-specific compound-dependent affinity for at least the portion of the compounds. A parameter dependent on the non-specific affinity of the surface for each one of at least the portion of the set of compounds in the test solution is measured and used to calculate the dissociation constant.